Immunization with rP22 induces protective immunity against Schistosoma mansoni: Effects on granuloma down-modulation and cytokine production  by Rezende, Cíntia M.F. et al.
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Schistosomiasis  remains  a signiﬁcant  public  health  problem  in  tropical  countries  and  it  is recognized
as  the most  important  human  helminth  infection  in  terms  of  morbidity  and  mortality.  Although  the
existing  antischistosomal  drugs  are  highly  effective,  they  do  not  prevent  against  reinfection  or  granuloma
formation.  Therefore,  vaccine  strategies  are  essential  for  the  control  of  schistosomiasis.  Our  group  recently
identiﬁed  the recombinant  (r) P22  protein,  a component  of  the  adult  worm  protein  fraction  PIII that
has  been  shown  to engender  protective  and  immunomodulatory  effects  on murine  schistosomiasis.  A
cDNA  clone  encoding  rP22  was  isolated  from  a  Schistosoma  mansoni  adult  worm  cDNA  library  using
anti-PIII  rabbit  serum;  it exhibited  complete  identity  with  S. mansoni  Sm21.7  EF-hand  antigen.  Confocal
microscopy  revealed  that  rP22  is  a tegument  protein  localized  on the  surface  of  S.  mansoni  miracidia  and
adult  worms.  Mice  immunized  with  rP22 exhibited  a 51%  and  22.5%  decrease  in adult  worm  burden  andranuloma down-modulation in  hepatic  eggs,  respectively.  Additionally,  rP22  vaccine  produced  a  reduction  in  60%  of  liver granuloma
size  and  71%  of  ﬁbrosis  in  mice,  suggesting  that  rP22  might  contribute  to  down-modulate  granulomatous
hypersensitivity  to S. mansoni  eggs.  Protective  immunity  in  mice  was associated  with  high  titers  of  rP22-
speciﬁc  IgG antibodies;  elevated  production  of  IFN-,  TNF-  and  IL-10;  and  a reduced  level of  IL-4.  In
conclusion,  these  ﬁndings  indicate  that  rP22-based  vaccines  could  be useful  to elicit protection  and  reduce
pathology  associated  to  schistosomiasis.. Introduction
Schistosomiasis is a human parasitic disease caused by trema-
odes of the genus Schistosoma that affects more than 207 million
ndividuals worldwide [1] and causes up to 250,000 deaths per
ear [2]. Furthermore, the impact of the severe and debilitating
ffects of schistosomiasis account for the loss of 4.5 million disabil-
ty adjusted life years (DALY) annually [3].
Currently, schistosomiasis control strategies are predominately
ased on the treatment of infected individuals with safe and effec-
ive drugs [4]. However, mass treatment has been proven to be
nsufﬁcient to stop disease transmission, prevent reinfection or
educe parasite-induced morbidity [1,5,6]. Therefore, a protective
Abbreviations: SWAP, Schistosoma mansoni soluble worm antigen preparation;
III  fraction or PIII, anionic protein fraction obtained from SWAP.
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anti-schistosomiasis vaccine would be valuable to current disease
control programs [7].
Desirable  characteristics of a schistosomiasis vaccine candidate
include not only the capacity to reduce worm burden and fecundity,
but also the capacity to down-regulate granulomatous responses
to eggs that become trapped in the host liver and intestines and
cause morbidity [8]. Although many antigens have already been
described as promising vaccine candidates against schistosomiasis,
the protection level achieved has been approximately 50%. How-
ever, there is common agreement that even a partial reduction
in worm burden could considerably reduce pathology and limit
parasite transmission [9].
Another  important aspect of potential vaccine antigens is the
determination of the type of immune response is elicited by immu-
nization [8]. Protective immunity against Schistosoma mansoni has
been the subject of numerous studies. In the murine model, the
immunological mechanisms involved in protection are related to
antibody responses and cellular immune response dependent on
Open access under the Elsevier OA license.CD4+ T cell-mediated IFN- responses [10–13]. Among cells and
cytokines involved in immunomodulation, CD4+ T cells and IL-
10 play an important role in granuloma formation and regulation
[14–17].
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Our group has been studying PIII, an anionic protein fraction
btained from the S. mansoni soluble worm antigen preparation
SWAP), which has been shown to reduce worm burden and gran-
loma formation in PIII-immunized mice after challenge infection
18,19]. PIII also decreased in vitro granuloma reactions by human
eripheral blood mononuclear cells from chronic schistosomiasis
atients [20]. Previous works have demonstrated that some anti-
enic components of PIII, such as P24 [16] and recombinant RP44
21], possess both protective and immunomodulating properties
gainst S. mansoni infection after mice immunization. However,
ther PIII components and their individual immunological activ-
ties against schistosomiasis remain unknown.
In this study, we describe and characterize the recombinant pro-
ein rP22, a component of the PIII fraction. rP22 was  identiﬁed as a
egument protein and it is identical to Sm21.7, a member of the EF-
and-containing parasite protein family that also exhibits dynein
ight chain (DLC) domain [22]. Further, we evaluated the ability of
P22 immunization in mice to induce protection against S. man-
oni infection, and its capacity of down-regulate granulomatous
ypersensitivity to parasite eggs.
. Materials and methods
.1.  Mice and parasites
Female  C57BL/6 mice aged six to eight weeks were purchased
rom the Federal University of Minas Gerais (UFMG) animal facil-
ty. All protocols involving animals were approved by the local
thics Committee on Animal Care (CETEA–UFMG # 043/2008).
. mansoni cercariae were maintained routinely on Biomphalaria
labrata snails at the Centro de Pesquisas Rene Rachou-Fiocuz
CPqRR); for infections, cercariae were prepared by exposing
nfected snails to light for 1 h to induce shedding. Cercarial num-
ers and viability were determined using a light microscope prior to
nfection.
.2. Antigen preparation
SWAP  and PIII preparations were produced and puriﬁed as
reviously described [20]. Brieﬂy, SWAP was prepared as soluble
upernatant ﬂuids from buffered saline homogenates of adult S.
ansoni worms. PIII was obtained from SWAP by FPLC using Q-
epharose anion-exchange chromatography with 5 mm × 90 mm
lass columns packed with Q-Sepharose beads sized between 45
nd 165 mm (Pharmacia, Uppsala, Sweden).
.3.  Cloning and sequencing of rP22 cDNA
The rP22 DNA sequence was obtained from a cDNA expres-
ion library constructed from mRNA of S. mansoni adult worms.
he expression library was screened using polyclonal rabbit IgG
ntibodies against PIII; identiﬁed clones were sequenced using
he DYEnamicTM ET dye terminator cycle sequencing MegaBACETM
it and the MegaBACE 1000 capillary sequencer (Amersham
iosciences, Buckinghamshire, England) as described previously
23]. The sequences obtained were compared with those already
eposited in the GenBank database using the Basic Local Align-
ent Search Tool (BLAST) algorithm available at the NCBI website
http://www.ncbi.nlm.nih.gov/Blast/).
Speciﬁc oligonucleotides were designed to amplify the cDNA
lone coding rP22 sequence. The 5′ and 3′ oligonucleotides, GGG
AC AAG TTT GTA CAA AAA AGC AGG CTT CGA AGG AGA TAG AAC
AT GGA TAG TCC AAT GGA AAA ATT TAT TC and GGG GAC CAC TTT
TA CAA GAA AGC TGG GTC GTT ACT TGG TGT ACG CCA AG, were
sed in a PCR reaction to amplify the complete open reading frame
f rP22. PCR was performed using Platinum Pfx enzyme (Invitrogen, Letters 141 (2011) 123– 133
Carlsbad,  USA); the reaction was initiated with one cycle of 5 min  at
94 ◦C, followed by 30 cycles of 30 s at 94 ◦C, 1 min at 52 ◦C, and 3 min
at 68 ◦C. PCR products were cloned by a BP recombination reaction
into pDONRTM221 cloning vector (Invitrogen, USA), according to
manufacturer speciﬁcations; plasmids were sequenced to conﬁrm
proper insertion. After producing and sequencing an entry clone, a
LR recombination reaction was  performed with pDONR-rP22 and
pETDEST42 to clone the full-length cDNA sequence of rP22 into an
expression vector (Invitrogen, USA).
2.4. Sequence analysis of rP22
The amino acid sequence of rP22 was obtained and used as a
query in Blast and PSI-Blast searches against the non-redundant
protein sequence database to identify rP22 orthologs (http://blast.
ncbi.nlm.nih.gov/Blast)  and to search for conserved domains
using the CDART program [24]. Primary structure analysis of
rP22 was performed using the Expasy (Expert Protein Analysis
System, http://ca.expasy.org/tools)  computer program. Molec-
ular weight (MW)  and isoelectric point (pI) were calculated
with the ProtParam tool (http://expasy.org/tools/protparam.
html). The identiﬁcation of signal peptide (SignalP 3.0,
http://www.cbs.dtu.dk/services/SignalP), and transmembrane
protein prediction (TMHMM,  http://www.cbs.dtu.dk/services/
TMHMM-2.0) were also performed by bioinformatics.
2.5. Expression of recombinant protein
Escherichia coli BL21 (DE3) (Invitrogen, USA) were transformed
with pETDEST42-rP22 expression vector to produce a recombi-
nant P22 that contained a C-terminal hexahistidine tag. For protein
expression, transformed cells were grown in 1L LB plus ampi-
cilin (OD600 = 0.6). Isopropyl--d-thiogalactopyranoside (IPTG)
was added to the culture to a ﬁnal concentration of 0.5 mM,  and cells
were incubated for 3–4 h at 37 ◦C. Cells were harvested by centrifu-
gation and resuspended in 30 ml  of binding buffer (20 mM sodium
phosphate, 0.5 M NaCl, 20–40 mM imidazole, pH 7.4). Cell suspen-
sions were then frozen and thawed three times. Next, the lysates
were submitted to three 30 s cycles of sonication to release the tar-
get protein. The fusion protein obtained in the supernatant after
centrifugation was then puriﬁed by metal afﬁnity chromatogra-
phy using the Akta Prime system (Amersham Biosciences, England)
under native conditions. Brieﬂy, the sample was  loaded onto a Ni2+-
NTA columns (5 ml  bed volume) pre-equilibrated with the same
buffer. The columns were washed with 10 bed volumes of the
binding buffer and were then eluted with 20–500 mM imidazole
linear gradient. The main peak was pooled, and the protein purity
of fractions was assessed using sodium dodecyl sulfate polyacry-
lamide gel electrophoresis (SDS-PAGE). Additionally, the elution
buffer was exchanged with Phosphate Buffered Saline pH 7.4 (PBS)
before use of this protein.
2.6.  Polyclonal antibody production
Polyclonal rabbit sera were produced against preparations of
PIII, recombinant P22 or native P24. Rabbits were inoculated with
100 g of rP22, P24 or PIII preparation by i.m. injections at 15-
day intervals with a total of three injections. PIII and recombinant
proteins were formulated with Freund’s adjuvant (complete Fre-
und’s adjuvant for the ﬁrst immunization and incomplete Freund’s
adjuvant (IFA) for the subsequent injections). Fifteen days after the
last inoculation, rabbits were exsanguinated [19]. The sera were
assayed for Western blot analysis and for the indirect immunoﬂu-
orescence assays.
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.7. Western blot analysis
Puriﬁed  rP22, SWAP or pellet of an E. coli clone expressing rP24
ragment (another PIII component) were submitted to SDS-PAGE,
ransferred to nitrocellulose membranes and blocked for 16 h at
oom temperature with PBS casein (1.6% of casein in PBS 1×). The
embranes were washed three times with PBST (PBS 1×, 0.05%
ween 20) and probed with anti-PIII, anti-rP22 or anti-rP24 rabbit
erum diluted 1:500, 1:10,000 and 1:500, respectively, in PBS with
.25% casein for 1 h at room temperature. Next, the membranes
ere washed three times and probed for 1 h with anti-rabbit IgG
onjugated to horseradish peroxidase (Sigma, St. Louis, MO,  USA)
iluted 1:10,000 in PBS–0.25% casein. After three washes, the mem-
ranes were treated with a solution containing 3,3′aminobenzidine
DAB) 600 g/ml, NiCl2 10 l/ml and H2O2 1 l/ml, diluted in PBS
×; the color reaction was stopped with distilled water.
.8.  Immunization of mice
Eight to ten week old female C57BL/6 mice were divided into
ve groups of seven mice each. Mice were subcutaneously injected
n the nape of the neck with either 50 g of rP22 or SWAP. First and
econd boosts were given 2 and 4 weeks, respectively, after the
nitial immunization. SWAP and rP22 protein concentrations for
accination were determined with a Micro BCA Protein Assay Kit
Thermo Scientiﬁc Co., Waltham, MA,  USA). The antigens rP22 and
WAP were formulated with 100 g of Corynebacterium parvum
nd 1 mg  of aluminum hydroxide (Al(OH)3) as adjuvant [16]. PBS 1×
r PBS 1× with C. parvum and Al(OH)3) were administered to saline
nd adjuvant control groups, respectively, following the same
mmunization protocol. To distinguish the two different time points
f the vaccination/infection protocol, mice group that received
P22 + adjuvant were named rP22-Vac. Mice that were vaccinated
ith rP22 + adjuvant and subsequently challenged were labeled
P22-VacCha group. rP22-Vac group mice were sacriﬁced 15 days
fter the third immunization; all other groups were challenged
ith cercariae after the last immunization and mice sacriﬁced after
 weeks of challenge infection. Three immunization experiments
ere performed independently as well as subsequent analysis of
rotection, antibody response and cytokine proﬁle.
.9. Challenge infection and worm burden assessment
Fifteen days after the last immunization, mice were challenged
hrough percutaneous exposure of abdominal skin to water con-
aining 25 cercariae (LE strain) for one hour. Sixty days after
hallenge, mice were sacriﬁced and adult worms were perfused
rom their portal veins [21]. Three independent experiments were
erformed to determine protection levels. Protection was calcu-
ated by comparing the number of worms recovered from each
accinated group compared with its respective control group using
he formula:
 Protection =
[
(C − I)
C
]
× 100
n  this formula, C represents the worms recovered from the adju-
ant control group and I represents the worms recovered from the
xperimental group.
.10.  Immunolocalization of rP22 in S. mansoni adult worms and
ggAdult  worms were recovered from perfused mice, and the liv-
rs of S. mansoni-infected mice were also removed to perform
onfocal microscopy studies. Parasites and tissues ﬁxed in Para-
last Plus (Sigma, USA) were used in section assays. Slices of Letters 141 (2011) 123– 133 125
7  m-thickness were deparafﬁnized with a xylol series and were
blocked with 1% BSA in PBST (Tween 20 0.05%) for 1 hr. Sec-
tions were next incubated with anti-rP22 rabbit serum diluted
1:50 in blocking buffer. Serum from a non-immunized rabbit was
used as a negative control. Samples were washed three times
with PBST and were incubated with anti-rabbit IgG antibodies
conjugated to Alexa Fluor 488 (Invitrogen, USA) diluted 1:100 in
blocking buffer containing Hoescht dye (Invitrogen, USA) to stain
cellular nuclei. The samples were washed three times and were
mounted onto the glass slides using Hydromount (National Diag-
nostics, Atlanta, USA). Parasites were then visualized using a Zeiss
510 Meta confocal microscope with an immersion objective. All
parameters and microscope settings used were maintained for all
samples.
2.11. rP22 and SWAP speciﬁc antibody production
Following immunization, serum samples from seven mice from
each experimental group were collected at two-week intervals. A
measurement of speciﬁc anti-rP22 or anti-SWAP antibodies was
performed using an indirect ELISA. Maxisorp 96-well microtiter
plates (Nunc, Roskilde, Denmark) were coated with 5 g/ml of
either rP22 or SWAP in carbonate–bicarbonate buffer, of pH 9.6
for 16 h at 4 ◦C. Plates were washed with PBS 0.05% Tween
20 and were then blocked for 1 h at room temperature with
200 l/well of PBS–casein (phosphate buffer saline, pH 7.2 with
1.6% casein). Next, 100 l of each serum sample diluted 1:800
(IgG) or 1:400 (IgG1 and IgG2a) in PBS 0.25% casein was added
to each well and was incubated for 1 h at room temperature.
Plate-bound antibodies were detected by peroxidase-conjugated
anti-mouse IgG, IgG1 and IgG2a (Southern Biotechnology Asso-
ciates, Inc., Birmingham, AL, USA) diluted in PBS–0.25% casein
1:5,000. The plates were developed by the addition of 100 l
of detection solution (R&D systems, Minneapolis, USA) contain-
ing tetramethylbenzidine (Thermo Scientiﬁc Pierce) and H2O2 in
each well; after 20 min, reactions were stopped with the addi-
tion of 50 l of 5% sulfuric acid per well. The plates were read at
450 nm in an ELISA plate reader (ELX 800 BIO-TEK Instruments
Inc.).
2.12. Cytokine analysis
Cytokine  experiments were performed using splenocyte cul-
tures from individual mice immunized with either rP22 or SWAP
plus C. parvum/Al(OH)3 (n = 7 for each group). Splenocytes were
isolated from macerated spleens of individual mice 10 days after
the third immunization or at 8 weeks post-infection. Cells were
washed twice with sterile PBS and were plated at a concentration
of 1 × 106 cells per well in RPMI 1640 medium (Gibco, Carlsbad, CA,
USA) supplemented with 10% FBS, 100 U/ml of penicillin G sodium,
100 g/ml of streptomycin sulfate, and 250 ng/ml of amphotericin
B. Splenocytes were maintained in culture with medium alone
or stimulated with rP22 (25 g/ml), SWAP (25 g/ml) or ConA
(1.6 g/ml), as previously described [25]. The 96-well plates (Nunc,
Denmark) were maintained in an incubator at 37 ◦C with 5% CO2.
For cytokine assays polymyxin B (30 g/ml) was added to the cul-
tures and this treatment completely abrogate the cytokine response
to LPS as previously described [26]. Culture supernatants were col-
lected after 24 h of rP22 or SWAP stimulation for TNF- analysis
and after 72 h for IL-10, IL-4, TGF- and IFN- analysis. IL-4, IL-
10, IFN-, TGF- and TNF- concentrations were measured using
Duoset ELISA kit (R&D Systems, USA) according to the manufac-
turer’s directions.
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sig. 1. In silico analysis of Schistosoma EF-hand- and dynein light domain-containing
egument antigen [I(H)A] (CAX72713.1) are aligned to show homologous domains (
osition  of each protein. EF-hand motifs are boxed in light grey, dynein domains ar
.13. Analysis of egg count in the liver tissue, granuloma area and
brosis
Livers from mice (7 mice per group) of control and experimental
roups immunized with rP22 or SWAP and infected with 25 cer-
ariae were collected 8 weeks post-infection in order to evaluate
he effect of immunization on granuloma formation and determine
he number of eggs present in tissue. Livers fragments were ﬁxed
ith DMSO-methyl alcohol in a proportion of 1:5. Fragments were
rocessed for Paraplast (Sigma, USA) embedding and histopatho-
ogical sections were cut using a microtome at 5 m.  Sections were
tained on a slide with hematoxilin–eosin (HE) or with Masson’s
richrome to measure granuloma area and ﬁbrosis, respectively.
he areas of individual granulomas were obtained through the
acBiophotonics ImageJ software analyzer. Fifteen granulomas
rom each mouse with a single well-deﬁned egg were randomly
hosen using a microscope with the 10× objective lens; granulomas
ere then scanned using JVC TK-1270/RGB microcamera. Using a
igital pad, the total area of each granuloma measured, and the
esults were expressed in square micrometers (m2). To calculate
he area of ﬁbrosis in the granulomas, the pixels of the collagen
reas were selected through the real image with subsequent cre-
tion of a binary image and obtain the area in m2. To count eggs
rapped in liver, a sample of the left lateral hepatic lobe of each ani-
al  was weighted and subsequently digested in 5% KOH [27]; three
-ml subsamples of the digestion ﬂuid were counted for each sam-
le. The mean count was used to determine eggs per gram (EPG) in
he liver.
.14. Statistical analysis
Statistical  analysis was performed with the ANOVA test using
he GraphPad Prism software package. The Bonferroni test was  used
o compare subgroups.
.  Results
.1. Cloning and molecular characterization of S. mansoni rP22The  full-length sequence of the S. mansoni cDNA encoding rP22
as obtained from an adult worm cDNA library using PCR with
peciﬁc oligonucleotides. The resulting full-length cDNA displayedins. The full amino acid sequences of rP22, Sm21.7 (XP 002569898) and S. japonicum
T). Numbers after each row indicate the residue position relative to the amino acid
d in dark grey (Pfam) and provisional calmodulin domains are underlined.
an  ORF of 555 bp, encoding a protein of 184 amino acids with a
predicted molecular mass of approximately 21.7 kDa and an iso-
electric point of 6.85. BlastP comparisons of the deduced S. mansoni
protein sequence in GenBank showed that the best match (E-
value = 2 ×10−105) was to S. mansoni Sm21.7 antigen; over 184
amino acids, rP22 exhibited complete identity and similarity to
Sm21.7 (Fig. 1). The next best match was  to a Schistosoma japon-
icum tegument antigen [I(H)A] with 76% identity. This protein
most likely represents an rP22 ortholog. Once rP22 was identical
Sm21.7 antigen, the signature EF-hand motif sequence present in
Sm21.7 was also identiﬁed in rP22 (residues 41–66, outlined by
a light grey box in Fig. 1) as well as the presence of a dynein-light
domain (residues 81–181). In contrast, S. japonicum tegument anti-
gen [I(H)A] possesses a multi-domain region with an EF-hand motif
inside a provisional calmodulin domain (residues 17–66) and does
not possess dynein-light domain. Additionally, as we did not iden-
tify a putative signal peptide or transmembrane domain in the rP22
sequence, it was  predicted as a soluble protein.
3.2. Production of recombinant rP22
The full-length DNA sequence of rP22 was cloned by recombi-
nation into the expression vector pET-DEST42 to produce a protein
that contained a C-terminal hexahistidine tag. Protein expression
was induced in transformed E. coli and resulted in a band at approx-
imately 26 kDa (Fig. 2A, lanes 2–5). Bacteria were then lysed by
sonication, and the lysate was separated into soluble and insolu-
ble fractions. The soluble fraction was  bound to a nickel-charged
column, and after afﬁnity chromatography through an imidazole
linear gradient was  performed, the eluted fractions containing rP22
were pooled. Protein yield after puriﬁcation was estimated to be
approximately 6.0 mg  of rP22/L culture (Fig. 2B, lane 2). For vacci-
nation experiments, the puriﬁed protein was dialyzed to remove
the imidazole.
3.3. rP22 is a component of the PIII fraction
Western blot assays were performed to determine the presence
of rP22 in the protective PIII protein fraction. Immunoblotting of
puriﬁed rP22 using anti-PIII polyclonal antibodies revealed a band
at 26 kDa that corresponds to rP22 and also demonstrating that
native P22 is a protein component of the PIII fraction (Fig. 2C, lane
2). Anti-PIII rabbit serum also revealed other proteins from SWAP
C.M.F. Rezende et al. / Immunology
Fig. 2. Expression, puriﬁcation and identiﬁcation of rP22 as a component of the
PIII  fraction. (A) SDS–PAGE of the supernatant of an E. coli clone expressing rP22.
Lanes: MW,  molecular weight marker; 1, negative control (BL21 not transformed);
2–5,  induction time (h) following the addition of 0.5 mM of IPTG to the cultures.
(B)  SDS–PAGE of puriﬁed rP22. The culture supernatant was puriﬁed through a Ni-
column. Lanes: MW,  molecular weight marker; 1, soluble worm antigen preparation
(SWAP); and 2, sample eluted from rP22 puriﬁcation. Western blot analysis of SWAP
and rP22 probed with anti-PIII serum (C); anti-rP22 serum (D) or anti-P24 serum
(E).  Two micrograms of SWAP (lane 1), puriﬁed rP22 (lane 2) and pellet of E. coli
expressing rP24 fragment (E-lane 3) were separated by SDS-PAGE and transferred
to  a nitrocellulose membrane. Next, the membranes were probed with serum from
a PIII-, rP22- or P24-vaccinated rabbit diluted 1:500, 1:10,000 and 1:500, respec-
tively. Lanes: MW,  molecular weight marker; SWAP; 2, sample eluted from rP22
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guriﬁcation; and 3, pellet of E. coli expressing rP24 fragment. The molecular weight
kDa) of molecular marker proteins is showed on the left.
Fig. 2C, lane 1). To determine the capacity of anti-rP22 serum
ecognize native P22 in the SWAP preparation, rP22 and SWAP
ere probed with anti-rP22 rabbit serum. A positive reaction was
etected for rP22 band (Fig. 2D, lane 2) and for a band at approxi-
ately 22 kDa that corresponds to the native P22 present in SWAP
reparation (Fig. 2D, lane 1). To demonstrate that P24, and rP22
re not the same protein, an immunoblotting of PIII, rP22 and P24-
xpressing clone using anti-P24 rabbit serum was performed. No
eaction was detected to rP22 (Fig. 2E, lane 2) and a positive reaction
as detected to a band at approximately 19 kDa that corresponds
o the expressed fragment of recombinant P24 (Fig. 2E, lane 3),
emonstrating that rP22 is a PIII-component different from P24. No
igniﬁcant reaction between PIII and anti-P24 serum was  detected
Fig. 2E, lane 1).
.4.  rP22 is a tegument protein of S. mansoni
Immunoﬂuorescence staining using rabbit serum raised against
P22 revealed through confocal microscopy that native P22 is
ocated on the surface of S. mansoni adult worms (Fig. 3D–N). The
egument-associated antigen P22 appeared to be highly expressed
n the surface of both male and female adult worms and it was not
ound in internal tissues of the parasite. No anti-native P22 anti-
ody staining was observed in sections incubated with pre-immune
abbit serum (Fig. 3A–C).In the present study, we also demonstrated P22 localization in
arasite eggs. Liver sections of S. mansoni infected mice were incu-
ated with rabbit serum against rP22. Liver sections containing
ranulomas show miracidia inside eggshell stained by anti-rP22, Letters 141 (2011) 123– 133 127
as  it can be seen by green band running around miracidia surface
(Fig. 3T–V), suggesting this antigen to be at the miracidium tegu-
mental layer. No staining was  observed in liver granuloma sections
incubated with naive rabbit serum (Fig. 3O–R).
3.5. Antibody proﬁle following mice immunization
The speciﬁc antibody response to either rP22 or SWAP was eval-
uated by ELISA. After three rounds of vaccination, signiﬁcant levels
of anti-rP22 IgG and anti-SWAP IgG were detected in the sera of
rP22- and SWAP-immunized mice, respectively (Fig. 4A and B).
Sera from SWAP vaccinated mice did not present signiﬁcant anti-
body levels for rP22. Conversely, sera from rP22-immunized mice
presented signiﬁcant IgG levels for SWAP (Fig. 4B). To determine
the IgG isotype proﬁle induced by immunization, speciﬁc IgG1 and
IgG2a to rP22 or SWAP were also analyzed. Signiﬁcant levels of
rP22-speciﬁc IgG1 and SWAP-speciﬁc IgG1were detected in the
sera of rP22- and SWAP-vaccinated mice, respectively (Fig. 4C and
D). Considerable anti-rP22 IgG2a and anti-SWAP IgG2a were also
detected in the sera of the mice immunized with rP22 and SWAP,
respectively, which remained almost constant after second immu-
nization (Fig. 4E and F). In addition, sera from rP22-immunized mice
presented considerable IgG2a levels for SWAP (Fig. 4F). There was
no signiﬁcant production of IgG or isotypes by mice primed with
PBS or adjuvant alone.
3.6.  Protective effect of rP22 vaccination
To investigate the protective activity induced by vaccination
with rP22 plus C. parvum/Al(OH)3 in murine model of S. mansoni
infection, mice were challenged with cercariae. The number of adult
worms recovered in the adjuvant control group and in the exper-
imental groups was determined and %protection was calculated
(Table 1). Animals immunized with rP22 plus C. parvum/Al(OH)3
and challenged with 25 cercariae showed a 51% reduction in adult
worm burden compared with the adjuvant control group in three
independent experiments (Table 1). The number of eggs in liver was
also assessed and rP22 vaccination led a 22.5% reduction in hepatic
egg burden compared to adjuvant control group, demonstrating its
protective capacity against S. mansoni challenge.
3.7. rP22 vaccination reduces hepatic granuloma size and ﬁbrosis
To  evaluate the effect of rP22 on reducing granuloma reac-
tions and ﬁbrosis, histological analysis was  performed by digital
morphometry. Ten days after the third immunization, mice were
challenged with 25 cercariae. After 8 weeks of challenge infection,
rP22- or SWAP-immunized mice were sacriﬁced and liver sam-
ples were taken for histological analysis. Hematoxilin and eosin
stained liver sections were then used to measure the size of indi-
vidual granulomas. rP22 vaccination reduced liver granuloma area
by 60% compared with mice that were immunized with adjuvant
alone (Fig. 5A and Table 1). Smaller granulomas were also in mice
immunized with SWAP; however these granulomas were not as
small as those observed in the rP22 immunized group. Liver sec-
tions were then stained by Masson’s trichrome to measure ﬁbrosis.
Liver from mice immunized with rP22 showed a 71% reduction of
ﬁbrosis compared with adjuvant control group (Fig. 5B; Table 1). A
signiﬁcant reduction of ﬁbrosis was  also detected in the hepatic tis-
sue of SWAP-vaccinated mice, but not as noteworthy as the ﬁbrosis
reduction observed in rP22-immunized group.3.8. Cytokine proﬁles following mice immunization
Cytokine experiments were performed using splenocyte cul-
tures from individual mice immunized with rP22 plus C.
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Fig. 3. Immunolocalization of rP22 in the S. mansoni tegument. Fluorescence confocal microscopy images and corresponding differential interface contrast (DIC) images
of  adult male (A–J) and female worms (K–N), and miracidia inside the egg (O–U) of S. mansoni are shown. Polyclonal anti-rP22 and secondary goat anti-rabbit antibodies
coupled to Alexa 488 (green) were used for ﬂuorescence detection of rP22. Serum from a naive rabbit was used as negative control for adult worm (A–C) and miracidium
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arvum/Al(OH)3 (n = 7 for each group) or from mice immunized
ith SWAP-adjuvant. Splenocytes from rP22-vaccinated mice weresolated either 15 days after the last vaccination (rP22-Vac)
r after 60 days of infection (rP22-VacCha). Splenocytes from
WAP-immunized mice were isolated after 60 days of infection.
roduction (IFN-, TNF-, IL-4, IL-10 and TGF-) were measuredetation of the references to color in this ﬁgure legend, the reader is referred to the
in  the supernatants of spleen cells cultured only in RPMI medium
containing fetal bovine serum or in the presence of rP22 or SWAP.
High levels of IFN- and the proinﬂammatory cytokine TNF-
were produced by rP22-stimulated splenocytes from the rP22-
immunized groups compared with the control or SWAP-stimulated
splenocytes (Fig. 6A and B). Additionally, higher levels of the
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Fig. 4. Speciﬁc IgG and isotype responses to rP22 and SWAP. Mice were immunized with either rP22 or SWAP at days 0, 15 and 30; and challenged with normal cercariae at
day  45. Triangles and arrows show the times of immunization and infection, respectively. rP22-speciﬁc IgG (A), IgG1 (C) and IgG2a (E); and SWAP-speciﬁc IgG (B), IgG1 (D)
and  IgG2a (F) were determined by ELISA. Sera were diluted 1/800 for total IgG and 1/400 for IgG1 and IgG2a. Saline, group that received PBS; adjuvant, group that received
C.  parvum/Al(OH)3 alone; SWAP, mice immunized with SWAP plus adjuvant; and rP22, mice vaccinated with rP22 plus adjuvant. The results are presented as the mean
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ith similar results (n = 7).
mmunomodulatory cytokine IL-10 and lower secretion of IL-4
ere also produced by rP22-stimulated splenocytes compared to
WAP-stimulated splenocytes (Fig. 6C and D). High levels of IFN-,
L-4 and the IL-10 were produced by SWAP-stimulated splenocytes
rom the SWAP-immunized groups compared with the control.
P22-stimulated splenocytes from SWAP-vaccinated mice pro-
uced higher levels of IFN- and  TNF- combined  with lower levels
f IL-4 when compared with SWAP-stimulated splenocytes from
able 1
rotective effect and liver granuloma size induced by C57BL/6 mice vaccination with rP22
Groups Total worms Mean ± SD Number of eggs per gram
liver  tissue Mean ± SD
Adjuvant 10.8 ± 1.6 5783 ± 800.5 
SWAP 6.8 ± 1.6* (37%)† 5299 ± 869* (8.4%)†
rP22-VacCha 5.3  ± 1.8* (51%)† 4481 ± 857.2* (22.5%)†
† Worm reduction rate (%); egg reduction rate (%) in liver tissue; granuloma or ﬁbrosis 
* Statistically signiﬁcant compared with the adjuvant control group (p < 0.05).
# Statistically signiﬁcant compared with SWAP group (p < 0.05).uvant groups (p < 0.05). Data are representative of three independent experiments
the  same group. As seen in the rP22-VacChan group, signiﬁcant IFN-
 production was  detected after infection of rP22-vaccinated mice
compared to rP22-Vac. IFN-, TNF- and IL-10 levels remained
high in the rP22-VanChan group, while IL-4 levels remained low
compared to rP22-Vac group. No signiﬁcant difference on TGF-
 production was  detected between rP22 and SWAP-stimulated
splenocytes of all groups (data not shown). These results indi-
cate that the immunization of mice with rP22 associated with C.
 and challenged with 25 S. mansoni cercariae.
Hepatic  granuloma area
(m2) Mean ± SD
Fibrosis area (m2) Mean ± SD
152,550 ± 15,444 151,780 ± 16,267
109,304 ± 15,258* (28.3%)† 100,960 ± 39,611* (33.5%)†
61,082 ± 16,556*,# (60%)† 44,157 ± 11,482*,# (71.0%)†
area reduction rate (%).
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Fig. 5. Photomicrographs of hepatic granulomas in C57BL/6 mice 8 weeks after challenge infection. Histological sections were stained with hematoxylin–eosin (A) or Masson’s
trichrome (B) to show granuloma size and ﬁbrosis, respectively, from mice groups immunized with adjuvant alone (control), SWAP + adjuvant, or rP22 + adjuvant.
Fig. 6. Cytokine proﬁles of mice immunized with rP22 or SWAP. Splenocytes isolated from mice of rP22-Vac group (mice vaccinated with rP22), rP22-VacCha group
(mice vaccinated with rP22 and subsequently challenged) or SWAP group (mice vaccinated with SWAP and subsequently challenged) were assayed for IFN-( (A), TNF-
( SWAP
m duced
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c (B), IL-4 (C) and IL-10 (D) production in response to in vitro stimulation with 
ean ± SD of each group. *Statistically signiﬁcant differences between cytokines pro
p  < 0.05). #Statistically signiﬁcant differences between rP22-stimulated splenocyte
ndependent experiments with similar results (n = 7).
arvum/Al(OH)3 adjuvants induced an immune response with per-
istent and increased levels of IFN-, TNF- and IL-10 combined
ith reduced levels of IL-4.
. Discussion
Schistosomiasis is a chronic debilitating parasitic disease that
epresents a major health problem in endemic areas, such as var-
ous parts of South America, Africa, and Southeast Asia [28,29].
ince current schistosomiasis control programs applied to reduce
orbidity and mortality have been proven inadequate and many
ommonly employed measures have been ineffective, there is a (25 g/ml), rP22 (25 g/ml) or medium alone as control. Results represent the
 after SWAP or rP22 stimulation compared with unstimulated splenocytes (control)
ared with SWAP-stimulated splenocytes (p < 0.05). Data are representative of three
consensus that the development of an appropriate protective vac-
cine would be a crucial part of the overall integrated control
strategy.
Innumerous antigenic preparations and puriﬁed native and
recombinant antigens from S. mansoni have been assayed for their
capacity to elicit protection against schistosomiasis. Additionally,
the recent publication of both the S. mansoni [30] and S. japon-
icum [31] genomes has brought to the scientiﬁc community an
enormous amount of data to be mined in the search for new vac-
cine candidates. In this context, our laboratory has identiﬁed a
protective protein fraction from adult worms, named PIII, which
reduced worm burden and decreased granuloma size in a murine
immunization model [18,20]. To identify PIII components and to
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etermine their role in the protective properties of this fraction, a
DNA library was constructed, and clones were screened using anti-
III serum. Herein, we identiﬁed rP22 protein as a component of
he protective PIII fraction and characterized the immune response
nduced following rP22 vaccination.
In this report, we determined that the rP22 amino acid sequence
s identical to Sm21.7 antigen. Sm21.7 contains one EF-hand motif
nd a dynein light chain domain at amino acid positions 41–66 and
1–181, respectively. The EF-hand motif is present in a group of
mportant parasite antigens, such as Sm22.6 and Sm21.6 [32,33].
hese surface proteins were recognized by antibodies from pro-
ected mice and by serum from S. mansoni patients that are resistant
o reinfection. Dynein light chain domain-containing proteins, such
s rP22, are likely components of the cytoskeleton and are involved
n the motility of vesicles and organelles along microtubules; they
ay  also provide a structural scaffold for parasite tegument. rP22
howed 76% of identity with the S. japonicum tegument antigen
I(H)A].
Additionally, we conﬁrmed by confocal ﬂuorescence
icroscopy that rP22 is located on the tegument of S. man-
oni adult worms and miracidia. This surface antigen was highly
xpressed on the tegument and absent in the internal tissues
f the parasite body. It is interesting to notice that rP22 is a
egument antigen, and not a secreted or transmembrane protein,
ecause neither a peptide signal nor a transmembrane domain
as detected by bioinformatic approaches. In accordance with
ur confocal ﬁndings, Braschi et al. examined a great number of
ynein-related proteins present in tegument extracts by proteomic
nalysis and concluded that the layer immediately beneath the
lasma membrane is largely composed of dynein homologues
hich form a macromolecular complex [34].
Tegument proteins, such as rP22, are important sources of
arasite antigens for the development of a schistosome vaccine,
ainly because tegument is a dynamic host-interactive layer that
s involved in innumerous parasite functions such as nutrition,
xcretion, osmoregulation, sensory reception, signal transduction
nd immune evasion and modulation [35,36]. Recently, publica-
ions have shown that some proteins located in the tegument,
uch as TSP-2 [27] and Sm-p80 [37], are able to induce high
evels of protection against S. mansoni infection in the murine
odel. To determine if rP22 conferred protection against S. man-
oni infection, immunized mice were challenged with cercariae and
orm burdens were assessed. Immunization with rP22 induced
 51% reduction in worm burden. Although rP22 is a compo-
ent of PIII, as conﬁrmed by western blot analysis with anti-PIII
erum, comparative analysis found that rP22 immunization was
ore efﬁcient in reducing worm burden compared to vaccination
ith the entire PIII fraction. Another component of PIII fraction,
 24 kDa protein (P24) also induced high levels of protection
gainst S. mansoni challenge [16]. Sera produced against P24 did
ot recognize rP22 band in western blot assay and conﬁrmed
hat rP22 and P24 were not the same antigen but different PIII
omponents.
Protective immunity against schistosomiasis involves both
umoral and cellular immune responses [13]. In this report, rP22-
mmunized mice produced signiﬁcant levels of anti-rP22 IgG, IgG1
nd IgG2a after the ﬁrst immunization. Additionally, sera from rP22
accinated mice presented signiﬁcant antibody levels for SWAP,
uggesting that rP22-speciﬁc antibodies were probably recogniz-
ng native P22 from SWAP. The dynamic IgG and isotype response
atterns to SWAP were similar to the antibody proﬁle elicited by
P22 immunization. Conversely, little antibody response to rP22
as detected in the sera from SWAP-immunized mice. These ﬁnd-
ngs are opposed to the results observed in western blot analysis
hich conﬁrmed a positive reaction for rP22 probed with anti-PIII
abbit serum, suggesting that range of native P22 concentration in Letters 141 (2011) 123– 133 131
the constitution of SWAP and PIII could explain the differences in
rP22 recognition pattern.
There  is lack of consensus regarding the desired type of immune
response that should be elicited against S. mansoni. In the irradiated
cercariae vaccination model, protection can be mediated through a
Th1, a Th2, or a mixed Th1/Th2 immune response [38]. The involve-
ment of IFN- in protective immunity to schistosomiasis is well
described in mice exposed to the irradiated cercariae vaccine [39].
The treatment of vaccinated mice with monoclonal anti-IFN- anti-
bodies totally abrogated the achieved protective immunity [11].
The use of IFN- knockout mice showed similar results and con-
ﬁrmed the essential role of IFN- in protective immunity against
murine schistosomiasis [12]. We  also demonstrated increased IFN-
 production in rP22-vaccinated mice that were challenged with
S. mansoni, suggesting that the protective effect of rP22 vacci-
nation could be related to the maintenance of high levels of
IFN-.
In the murine model of S. mansoni infection, the CD4+ Th cell
response evolves from a Th1- to a Th2-dominated response fol-
lowing egg production by adult worms [40,41]. During chronic
infection, the Th2-dominated response is downregulated at the
same time as there is a slight increase in the Th1 response.
This phenomenon marks the transition into the chronic stages
of the infection, which is associated with the downmodulation
of  granuloma size and results in smaller, newly formed, periovu-
lar granulomas and reduced cytokine expression by CD4+ T cells
[42,43]. Herein, we demonstrated that rP22-vaccinated mice that
were challenged with S. mansoni produced high levels of IFN- after
immunization and during transition to chronic stage. The main-
taining high levels of IFN- may  have contributed to balance the
Th2-dominated immune response during chronic stage of S. man-
soni, since a signiﬁcant decrease of ﬁbrosis and granuloma size were
detected in rP22-immunized mice.
In regards to new antigens in the schistosomiasis vaccine
research ﬁeld, the anti-morbidity effect is an important require-
ment to be evaluated [7]. The granulomatous reactions that occur
around parasite eggs represent the major pathology associated
with schistosomiasis; further, the intensity of these reactions cor-
relates with host morbidity [17,44,45]. In murine schistosomiasis,
pathology is induced by a CD4+ Th2 driven granulomatous response
directed against schistosome eggs lodged in the host liver. The
Th2 cytokines IL-4 and IL-13 drive this response, whereas IL-
10, IL13R2, IFN- and inducible regulatory T-cells act to limit
schistosome induced pathology [46–49]. In our study, histopatho-
logical analysis revealed a signiﬁcant reduction in granuloma
size and ﬁbrosis in the livers of mice vaccinated with rP22. This
immunomodulatory effect might be associated in part to the main-
taining high levels of IL-10 also observed for rP22-immunized mice.
Similar results were described for PIII immunization, showing that
native P22 could play an important role in the granuloma down-
modulation promoted by PIII immunization.
Previous work has also demonstrated that PIII and P24, a PIII
component, were able to reduce granulomatous reactions in vitro
and in vivo after cercarial challenge of immunized mice [16,19]. Our
results suggest that rP22 anti-morbidity effects might be correlated
with the capacity of rP22 to elicit both IFN- and IL-10 production.
We suggest that balance between IFN- and IL-10 may be crucial for
the protective and immunomodulating properties of rP22. Thus, we
believe that the combination of rP22 with multiple target antigens
could induce effective protection against the S. mansoni, leading the
development of an appropriate antischistosomiasis vaccine.Conﬂict  of interests
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